L D Lewis

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. ncbi request reprint The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer
    Lionel D Lewis
    Department of Medicine, Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Cancer Chemother Pharmacol 49:375-84. 2002
  2. pmc Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms
    L D Lewis
    Section of Clinical Pharmacology, Department of Medicine, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, HBox 7506, One Medical Center Drive, Lebanon, New Hampshire 03756, USA
    Br J Clin Pharmacol 62:1-4. 2006
  3. ncbi request reprint Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
    Antonius A Miller
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    J Clin Oncol 25:3055-60. 2007
  4. pmc The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)
    Lionel D Lewis
    Sections of Clinical Pharmacology and Hematology Oncology, Department of Medicine, The Geisel School of Medicine at Dartmouth, The Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Pharmacogenet Genomics 23:29-33. 2013
  5. ncbi request reprint Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production
    L D Lewis
    Department of Medicine and Pharmacology and Molecular Sciences Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hum Exp Toxicol 23:173-85. 2004
  6. ncbi request reprint Technology evaluation: ING-1, XOMA
    Lionel D Lewis
    Section of Clinical Pharmacology, Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH 03756, USA
    Curr Opin Mol Ther 5:433-6. 2003
  7. ncbi request reprint Preclinical and clinical studies: a preview of potential future applications of erythropoietic agents
    Lionel D Lewis
    Departments of Medicine Pharmacology and Toxicology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Semin Hematol 41:17-25. 2004
  8. ncbi request reprint A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
    Lionel D Lewis
    Sections of Clinical Pharmacology and Hematology Oncology, Department of Medicine, Dartmouth Medical School, The Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 13:3302-11. 2007
  9. ncbi request reprint Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu
    L D Lewis
    Department of Medicine, Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    J Immunol Methods 248:149-65. 2001
  10. ncbi request reprint Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo
    P K Wallace
    Department of Microbiology, HB7556, Dartmouth Medical School and the Immunology Immunotherapy Program of the Norris Cotton Cancer Center, 1 Medical Center Drive, Lebanon, NH 03756, USA
    J Immunol Methods 248:167-82. 2001

Detail Information

Publications30

  1. ncbi request reprint The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer
    Lionel D Lewis
    Department of Medicine, Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Cancer Chemother Pharmacol 49:375-84. 2002
    ..MDX-H210 is a Fab'xFab' bispecific antibody (BsAb) constructed chemically by crosslinking Fab' mAb 520C9 (anti-HER-2/neu) and humanized Fab' mAbH22 (anti-CD64)...
  2. pmc Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms
    L D Lewis
    Section of Clinical Pharmacology, Department of Medicine, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, HBox 7506, One Medical Center Drive, Lebanon, New Hampshire 03756, USA
    Br J Clin Pharmacol 62:1-4. 2006
  3. ncbi request reprint Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
    Antonius A Miller
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
    J Clin Oncol 25:3055-60. 2007
    ..We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction...
  4. pmc The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)
    Lionel D Lewis
    Sections of Clinical Pharmacology and Hematology Oncology, Department of Medicine, The Geisel School of Medicine at Dartmouth, The Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Pharmacogenet Genomics 23:29-33. 2013
    ..We conclude that the relationship between docetaxel-associated neutropenia and polymorphisms in drug transporters identified in Japanese patients was not confirmed in this cohort of US cancer patients...
  5. ncbi request reprint Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production
    L D Lewis
    Department of Medicine and Pharmacology and Molecular Sciences Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hum Exp Toxicol 23:173-85. 2004
    ..These findings support the hypothesis that mtDNA is one of the intracellular targets involved in the pathogenesis of AZT-associated bone marrow progenitor cell toxicity...
  6. ncbi request reprint Technology evaluation: ING-1, XOMA
    Lionel D Lewis
    Section of Clinical Pharmacology, Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH 03756, USA
    Curr Opin Mol Ther 5:433-6. 2003
    ..In November 2000, ING-1 entered phase I trials in the US and by February 2002, phase I/II trials had been initiated...
  7. ncbi request reprint Preclinical and clinical studies: a preview of potential future applications of erythropoietic agents
    Lionel D Lewis
    Departments of Medicine Pharmacology and Toxicology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Semin Hematol 41:17-25. 2004
    ..Erythropoietin may have benefits in retinal disease, peripheral neuropathy, and myocardial ischemia. Thus, accumulating evidence suggests that erythropoietic agents may have clinical utility outside CT-related anemia...
  8. ncbi request reprint A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
    Lionel D Lewis
    Sections of Clinical Pharmacology and Hematology Oncology, Department of Medicine, Dartmouth Medical School, The Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 13:3302-11. 2007
    ..We hypothesized that the pharmacokinetics and pharmacodynamics of docetaxel, an i.v. administered cytotoxic and substrate for CYP3A4, CYP3A5, and ABCB1, would differ between African-American and Caucasian patients...
  9. ncbi request reprint Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu
    L D Lewis
    Department of Medicine, Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    J Immunol Methods 248:149-65. 2001
    ..MDX-H210 is a Fab'xFab' bispecific antibody (BsAb) constructed chemically by crosslinking Fab' mAb 520C9 (anti-HER-2/neu) and Fab' mAbH22 (anti-CD64)...
  10. ncbi request reprint Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo
    P K Wallace
    Department of Microbiology, HB7556, Dartmouth Medical School and the Immunology Immunotherapy Program of the Norris Cotton Cancer Center, 1 Medical Center Drive, Lebanon, NH 03756, USA
    J Immunol Methods 248:167-82. 2001
    ....
  11. ncbi request reprint Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu
    T Schwaab
    Uro-Oncology Program, Norris Cotton Cancer Center and Section of Urology and Immunology and Immunotherapy Research Programs, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
    J Immunother 24:79-87. 2001
    ....
  12. ncbi request reprint Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity
    C P G Tretter
    Norris Cotton Cancer Center s Immunology and Immunotherapy Program, Section of Hematology Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    J Chemother 15:472-9. 2003
    ..A431 epidermoid carcinoma cells pretreated with IC20 growth inhibitory concentrations of taxanes enhanced interferon gamma activated monocyte mediated ADCC killing through MDXH447...
  13. ncbi request reprint Delayed sequelae after acute overdoses or poisonings: cranial neuropathy related to ethylene glycol ingestion
    L D Lewis
    Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Clin Pharmacol Ther 61:692-9. 1997
    ..This case serves to introduce a discussion of agents that cause delayed complications after their acute toxic ingestion...
  14. ncbi request reprint American Board of Clinical Pharmacology fellowship training and certification in clinical pharmacology: educational value and future needs for the discipline
    L D Lewis
    Section of Clinical Pharmacology, Department of Medicine, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Clin Pharmacol Ther 81:134-7. 2007
    ..We also explore how ABCP certification adds value to both individual trainees and the discipline in the evolving world of clinical therapeutics and research in human pharmacology...
  15. ncbi request reprint Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments
    Thomas W McAllister
    Department of Psychiatry, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Curr Psychiatry Rep 6:364-71. 2004
    ..Emerging theories about the role of selected genetic polymorphisms in heightening the vulnerability to chemotherapy-induced cognitive decline will be described...
  16. ncbi request reprint Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)
    Raymond P Perez
    Section of Hematology Oncology, Department of Medicine, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 12:7079-85. 2006
    ..A phase I trial tested the hypothesis that UCN-01 abrogates cisplatin-induced cell cycle arrest (in tumors) at tolerable doses...
  17. ncbi request reprint Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas
    J M Pipas
    Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Int J Radiat Oncol Biol Phys 50:1317-22. 2001
    ..To determine the maximum tolerated dose and dose-limiting toxicity associated with twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas...
  18. ncbi request reprint Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells
    T K Yeo
    Section of Clinical Pharmacology, Department of Medicine, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Hum Exp Toxicol 26:911-21. 2007
    ..Therefore, the molecular target(s) by which gemcitabine and 2',3'-dideoxycytidine produce mitochondrial abnormalities in these cells appear to be different...
  19. ncbi request reprint A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer
    Konstantin H Dragnev
    Sections of Hematology Oncology and Clinical Pharmacology, Department of Medicine, Dartmouth Medical School, Hanover, NH 03755, USA
    Clin Cancer Res 13:1794-800. 2007
    ..The relationship between bexarotene levels and biomarker changes in tumor tissues has not been previously studied...
  20. pmc Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells
    Christina Donnelly
    Department of Medicine, Section of Endocrinology and Metabolism, and the Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Nutr Cancer 61:114-22. 2009
    ..Rescue from the antiproliferative effect of CLA by palmitic acid indicates that reduced tumor lipogenesis is a major mechanism for the anticancer effects of CLA...
  21. ncbi request reprint Food effects on oral agents
    Lionel D Lewis
    Dartmouth Medical School, Hanover, NH 03755, USA
    Clin Adv Hematol Oncol 5:589-90. 2007
  22. ncbi request reprint Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol
    N J Reddy
    Section of Clinical Pharmacology and Toxicology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Clin Pharmacol Ther 81:114-21. 2007
    ..Treatment with carbidopa/levodopa improved cogwheel rigidity and bradykinesia in both patients. We conclude that acute Parkinsonism is one of the lesser-recognized devastating complications of both ethylene glycol and methanol poisoning...
  23. ncbi request reprint Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism
    Hong Kee Lee
    Department of Pathology, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, United States
    Clin Chim Acta 367:196-200. 2006
    ..Oxycodone has become widely used in the clinic for the treatment of chronic pain. This reflects its favorable pharmacokinetics and side effect profiles...
  24. ncbi request reprint Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma
    Peter Borchmann
    Klinik I für Innere Medizin der Universität Köln, Joseph Stelzmannstrasse 9, 50924 Köln, Germany
    Blood 100:3101-7. 2002
    ..H22xKi-4 shows activity in heavily pretreated HL patients warranting further clinical evaluation...
  25. ncbi request reprint Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs
    Margaret C McEntee
    Section of Oncology, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Am J Vet Res 67:1057-62. 2006
    ..To determine the maximum tolerated dose and characterize the pharmacokinetic disposition of an orally administered combination of docetaxel and cyclosporin A (CSA) in dogs with tumors...
  26. ncbi request reprint Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA
    Clin Cancer Res 13:3293-301. 2007
    ..v. infusion without premedication every 3 weeks, determine the maximum tolerated dose and the phase II recommended dose of AI-850, study the pharmacokinetics of paclitaxel in this new formulation, and seek evidence of anticancer activity...
  27. ncbi request reprint Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity
    Son B Le
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 282:8860-72. 2007
    ....
  28. ncbi request reprint The effects of ethidium bromide induced loss of mitochondrial DNA on mitochondrial phenotype and ultrastructure in a human leukemia T-cell line (MOLT-4 cells)
    Ray Armand
    Section of Clinical Pharmacology, Department of Medicine, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Toxicol Appl Pharmacol 196:68-79. 2004
    ..This data suggested that a glycolytic pathway product, possibly ATP, was required for the maintenance of Deltapsi(m) in MOLT-4 rho(0) cells...
  29. doi request reprint Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs
    Andrea B Flory
    Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Am J Vet Res 69:1316-22. 2008
    ..To characterize oral bioavailability and pharmacokinetic disposition of etoposide when the IV formulation was administered orally to dogs...
  30. ncbi request reprint Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas
    Kenneth M Rassnick
    Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Am J Vet Res 67:510-6. 2006
    ..To determine the maximally tolerated dose (MTD) and dose-limiting toxicosis (DLT) of ifosfamide in tumor-bearing cats...